About
Bilayer Therapeutics is a development-stage company founded by a team of world-renowned drug development and delivery experts and gastroenterologists. Its technology stimulates the body’s innate mechanisms for regulating metabolism and motility by targeting the receptor TGR5 and by increasing native incretin levels such as GLP-1. It achieves these effects by delivering the naturally occurring bile acid chenodeoxycholate via a proprietary bilayer tablet technology.
The company is developing innovative first-in-class treatments for a range of metabolic and motility disorders, initially for metabolic disorder (obesity, diabetes) with its drug candidate BL-050 and for motility disorders such as chronic constipation with its drug candidate BL-010.
Cambridge